More NewsRead More
Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
August 10, 2016
Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis
July 07, 2016
Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings
June 06, 2016
Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare Conference
June 02, 2016
Protalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 09, 2016
Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update
March 08, 2016
Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium™ 2016
March 03, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here